<DOC>
	<DOC>NCT00256711</DOC>
	<brief_summary>This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day cycle) in chemonaïve, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.</brief_summary>
	<brief_title>Phase II Iressa Versus Vinorelbine (INVITE)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirmed NSCLC and willing to provide paraffin embedded tumour tissue NSCLC locally advanced (Stage IIIB) or metastatic (stage IV) disease, not amenable to curative surgery or radiotherapy chemonaïve, life expectancy of 12 weeks WHO Performance status &lt;= 2 Newly diagnosed CNS metastases Less than 4 weeks since completion of radiotherapy or persistence of any radiotherapy related toxicity. Hypersensitivity to ZD1839 or intravenous vinorelbine Prior treatment with EGFR inhibitors Other coexisting malignancies ALT/AST &gt;2.5 x ULRR ANC &lt; 2.0 x 10^9/L or platelets &lt; 100 x 10^9/L</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Locally advanced or metastatic NSCLC.</keyword>
	<keyword>Stage IIIb or Stage IV lung cancer</keyword>
</DOC>